person · Reporting owner

DILLY STEPHEN GEORGE

Disclosed activity across 4 companies

Tapewire entity: 36739
SEC CIK: 0001389147

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aimmune Therapeutics, Inc.AIMT · Entity 145931	Director · President and CEO	June 11, 2018	June 13, 2018
CODEXIS, INC.CDXS · Entity 6428	Director	June 17, 2026	June 18, 2026
SANGAMO THERAPEUTICS, INCSGMO · Entity 7038	Director	May 18, 2020	June 03, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aimmune Therapeutics, Inc.

Report date June 11, 2018 · Filed June 13, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.0001 par valueSEC Table I · non-derivative	Direct	315,308	Ending reported balance After 2018-06-11 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2018-06-11 · Exercise / conversion · Acquired 29,457 · Balance 344,765 Row 2 · 2018-06-11 · Sale · Disposed 29,457 · Balance 315,308 F1: This sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person. F2: The transaction was executed in multiple trades in prices ranging from $30.51 to $31.18, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.02 · Expires 2025-05-18	Direct	295,942	Reported balance After 2018-06-11 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-06-11 · Exercise / conversion · Disposed 29,457 · Balance 295,942 F8: The option is immediately exercisable in full or in part. The shares vest pursuant to the following schedule: One forty-eighth (1/48th) of the shares subject to the option vest in 48 successive, equal monthly installments measured from May 13, 2015, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
Common Stock, $0.0001 par valueSEC Table I · non-derivative	IndirectBy GRAT 2	12,009	Reported balance Holding disclosure · report date 2018-06-11 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 12,009 F3: These shares are held by Stephen G. Dilly, Trustee, The Stephen G. Dilly 2016 Grantor Retained Annuity Trust DTD August 12, 2016 (the "Second Dilly Trust"). Dr. Dilly has sole voting, investment and dispositive power over the shares held by the Second Dilly Trust.
Common Stock, $0.0001 par valueSEC Table I · non-derivative	IndirectBy Wife's GRAT 2	12,009	Reported balance Holding disclosure · report date 2018-06-11 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 12,009 F4: These shares are held by Edwina Lynette Mullens, Trustee, The Edwina Lynette Mullens 2016 Grantor Retained Annuity Trust DTD August 12, 2016 (the "Second Mullens Trust"). Ms. Mullens has sole voting, investment and dispositive power over the shares held by the Second Mullens Trust. Dr. Dilly disclaims beneficial ownership of the shares held by the Second Mullens Trust.
Common Stock, $0.0001 par valueSEC Table I · non-derivative	IndirectBy Family Trust	25,532	Reported balance Holding disclosure · report date 2018-06-11 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 25,532 F5: These shares are held by Stephen G. Dilly and Edwina Lynette Mullens as Trustees of The Dilly Family Trust dated October 9, 2002 (the "Family Trust"). Dr. Dilly and Ms. Mullens have joint voting, investment and dispositive power over the shares held by the Family Trust.
Common Stock, $0.0001 par valueSEC Table I · non-derivative	IndirectBy Child's Trust 1	41,075	Reported balance Holding disclosure · report date 2018-06-11 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 41,075 F6: These shares are held by Stephen G. Dilly and Edwina Lynette Mullens as Trustees of The Frederick S W Dilly 2015 Irrevocable Trust dated June 23, 2015 (the "Frederick S W Dilly Trust"). Dr. Dilly and Ms. Mullens have joint voting, investment and dispositive power over the shares held by the Frederick S W Dilly Trust.
Common Stock, $0.0001 par valueSEC Table I · non-derivative	IndirectBy Child's Trust 2	41,075	Reported balance Holding disclosure · report date 2018-06-11 · row 7 Holding and transaction disclosures are not merged. 1 source row Row 7 · Balance 41,075 F7: These shares are held by Edwina Lynette Mullens and Stephen G. Dilly as Trustees of The Harriet F.L. Dilly 2015 Revocable Trust dated June 23, 2015 (the "Harriet F.L. Dilly Trust"). Dr. Dilly and Ms. Mullens have joint voting, investment and dispositive power over the shares held by the Harriet F.L. Dilly Trust.

Filing footnotes · ownership attribution and instrument terms

F1: This sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.

F2: The transaction was executed in multiple trades in prices ranging from $30.51 to $31.18, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.

F3: These shares are held by Stephen G. Dilly, Trustee, The Stephen G. Dilly 2016 Grantor Retained Annuity Trust DTD August 12, 2016 (the "Second Dilly Trust"). Dr. Dilly has sole voting, investment and dispositive power over the shares held by the Second Dilly Trust.

F4: These shares are held by Edwina Lynette Mullens, Trustee, The Edwina Lynette Mullens 2016 Grantor Retained Annuity Trust DTD August 12, 2016 (the "Second Mullens Trust"). Ms. Mullens has sole voting, investment and dispositive power over the shares held by the Second Mullens Trust. Dr. Dilly disclaims beneficial ownership of the shares held by the Second Mullens Trust.

F5: These shares are held by Stephen G. Dilly and Edwina Lynette Mullens as Trustees of The Dilly Family Trust dated October 9, 2002 (the "Family Trust"). Dr. Dilly and Ms. Mullens have joint voting, investment and dispositive power over the shares held by the Family Trust.

F6: These shares are held by Stephen G. Dilly and Edwina Lynette Mullens as Trustees of The Frederick S W Dilly 2015 Irrevocable Trust dated June 23, 2015 (the "Frederick S W Dilly Trust"). Dr. Dilly and Ms. Mullens have joint voting, investment and dispositive power over the shares held by the Frederick S W Dilly Trust.

F7: These shares are held by Edwina Lynette Mullens and Stephen G. Dilly as Trustees of The Harriet F.L. Dilly 2015 Revocable Trust dated June 23, 2015 (the "Harriet F.L. Dilly Trust"). Dr. Dilly and Ms. Mullens have joint voting, investment and dispositive power over the shares held by the Harriet F.L. Dilly Trust.

F8: The option is immediately exercisable in full or in part. The shares vest pursuant to the following schedule: One forty-eighth (1/48th) of the shares subject to the option vest in 48 successive, equal monthly installments measured from May 13, 2015, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

CODEXIS, INC.

Report date June 17, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.48 · Expires 2036-06-17	Direct	66,350	Reported balance After 2026-06-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-17 · Grant · Acquired 66,350 · Balance 66,350 F1: This option vests and becomes exercisable with respect to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This option vests and becomes exercisable with respect to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date.

SANGAMO THERAPEUTICS, INC

Report date May 18, 2020 · Filed June 03, 2020 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	15,000	Reported balance After 2020-05-18 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2020-05-18 · Grant · Acquired 10,000 · Balance 15,000 F1: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such date and subject to acceleration as provided in the 2018 EIP, as amended. F2: This Form 4/A is being filed solely to correct the stated grant amounts which were erroneously reported on Form 4 filed on behalf of the Reporting Person on May 20, 2020. Pursuant to the 2018 EIP, as amended, and the Automatic Grant Program for Non-Employee Directors thereunder, the annual grant amounts increased effective with the approval of the 2018 EIP, as amended, by the stockholders of the Issuer on May 18, 2020. Such previously filed Form 4 incorrectly stated grant amounts pursuant to the Automatic Grant Program for Non-Employee Directors prior to such amendment and restatement of the 2018 Equity Incentive Plan.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.46 · Expires 2030-05-17	Direct	20,000	Reported balance After 2020-05-18 transaction · row 2 Amendment: may correct only part of an earlier disclosure. 1 source row Row 2 · 2020-05-18 · Grant · Acquired 20,000 · Balance 20,000 F3: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended). The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Continuous Service (as defined in the 2018 EIP, as amended) over the 12-month period measured from the grant date and subject to acceleration as provided in the 2018 EIP, as amended.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such date and subject to acceleration as provided in the 2018 EIP, as amended.

F2: This Form 4/A is being filed solely to correct the stated grant amounts which were erroneously reported on Form 4 filed on behalf of the Reporting Person on May 20, 2020. Pursuant to the 2018 EIP, as amended, and the Automatic Grant Program for Non-Employee Directors thereunder, the annual grant amounts increased effective with the approval of the 2018 EIP, as amended, by the stockholders of the Issuer on May 18, 2020. Such previously filed Form 4 incorrectly stated grant amounts pursuant to the Automatic Grant Program for Non-Employee Directors prior to such amendment and restatement of the 2018 Equity Incentive Plan.

F3: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended). The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Continuous Service (as defined in the 2018 EIP, as amended) over the 12-month period measured from the grant date and subject to acceleration as provided in the 2018 EIP, as amended.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Sierra Oncology, Inc.

Report date July 01, 2022 · Filed July 01, 2022

Section 16 reporting ended · disclosed 2022-07-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-07-01 transaction · row 1 1 source row Row 1 · 2022-07-01 · Disposition to issuer · Disposed 5,000 · Balance 0
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.03 · Expires 2030-06-01	Direct	Reported balance After 2022-07-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-07-01 · Disposition to issuer · Disposed 520,000 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F1: The option vested as to 25% of the total shares on June 1, 2021, and then the remaining shares vest in equal monthly installments over the following 36 months, with 100% of the total shares vested on June 1, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.15 · Expires 2030-08-12	Direct	Reported balance After 2022-07-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-07-01 · Disposition to issuer · Disposed 260,000 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F3: On August 12, 2020, the Reporting Person was granted an option to purchase 260,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.73 · Expires 2031-03-15	Direct	Reported balance After 2022-07-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-07-01 · Disposition to issuer · Disposed 92,000 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F4: The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.54 · Expires 2032-03-14	Direct	Reported balance After 2022-07-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-07-01 · Disposition to issuer · Disposed 165,000 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F5: The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vested as to 25% of the total shares on June 1, 2021, and then the remaining shares vest in equal monthly installments over the following 36 months, with 100% of the total shares vested on June 1, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.

F3: On August 12, 2020, the Reporting Person was granted an option to purchase 260,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria.

F4: The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date.

F5: The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 25, 2016 Filed Nov 15, 2016 21:05 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	GiftCommon Stock, $0.0001 par value	14,447	$0.00	$0.00	Disclosure SEC source: 0000899243-16-033506 · doc4.xml · nonDerivative · entry 3 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · By Wife Disclosed balance after: 14,447 F5 · kind: This transaction involved a gift of securities previously held indirectly by Edwina Lynette Mullens, as Trustee of The Edwina Lynette Mullens 2015 Grantor Retained Annuity Trust dated June 23, 2015 (the "First Mullens Trust"). Such shares were transferred from the First Mullens Trust to Reporting Person's wife on July 25, 2016. Dr. Dilly disclaims beneficial ownership of the shares held by Ms. Mullens. Read SEC document
July 25, 2016 Filed Nov 15, 2016 21:05 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	GiftCommon Stock, $0.0001 par value	14,447	$0.00	$0.00	Disclosure SEC source: 0000899243-16-033506 · doc4.xml · nonDerivative · entry 2 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · By GRAT 1 Disclosed balance after: 51,403 F1 · kind: This transaction involved a gift of securities previously held indirectly by Stephen G. Dilly, as Trustee of The Stephen G. Dilly 2015 Grantor Retained Annuity Trust dated June 23, 2015 (the "First Dilly Trust"). Such shares were transferred from the First Dilly Trust to Reporting Person on July 25, 2016. F4 · ownership.nature: These shares are held by the First Dilly Trust. Dr. Dilly has sole voting, investment and dispositive power over the shares held by the First Dilly Trust. Read SEC document
July 25, 2016 Filed Nov 15, 2016 21:05 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	GiftCommon Stock, $0.0001 par value	14,447	$0.00	$0.00	Disclosure SEC source: 0000899243-16-033506 · doc4.xml · nonDerivative · entry 1 DILLY STEPHEN GEORGE · CIK 0001389147 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 779,755 F1 · kind: This transaction involved a gift of securities previously held indirectly by Stephen G. Dilly, as Trustee of The Stephen G. Dilly 2015 Grantor Retained Annuity Trust dated June 23, 2015 (the "First Dilly Trust"). Such shares were transferred from the First Dilly Trust to Reporting Person on July 25, 2016. F2 · balance_after: A portion of these shares is subject to a right of repurchase held by the Issuer. F3 · balance_after: Includes 14,447 shares previously held indirectly by the First Dilly Trust. Such shares were transferred from the First Dilly Trust to Reporting Person on July 25, 2016. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.